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The mRNA N6-methyladenosine (m6A) modification has emerged as an essential regulator of normal and malignant
hematopoiesis. Inactivation of the m6A mRNA reader YTHDF2, which recognizes m6A-modified transcripts to promote
m6A-mRNA degradation, results in hematopoietic stem cell (HSC) expansion and compromises acute myeloid
leukemia. Here we investigate the long-term impact of YTHDF2 deletion on HSC maintenance and multilineage
hematopoiesis. We demonstrate that Ythdf2-deficient HSCs from young mice fail upon serial transplantation, display
increased abundance of multiple m6A-modified inflammation-related transcripts, and chronically activate
proinflammatory pathways. Consistent with the detrimental consequences of chronic activation of inflammatory
pathways in HSCs, hematopoiesis-specific Ythdf2 deficiency results in a progressive myeloid bias, loss of lymphoid
potential, HSC expansion, and failure of aged Ythdf2-deficient HSCs to reconstitute multilineage hematopoiesis.
Experimentally induced inflammation increases YTHDF2 expression, and YTHDF2 is required to protect HSCs from this
insult. Thus, our study positions YTHDF2 as a repressor of inflammatory pathways in HSCs and highlights the
significance of m6A in long-term HSC maintenance.
Introduction
Emerging evidence indicates the importance of the mRNA N6-
methyladenosine (m6A) modification in hematopoietic stem
cell (HSC) biology and leukemic transformation (Vu et al.,
2019). m6A is the most abundant internal mRNA modifica-
tion, which is cotranscriptionally installed by the “m6A
writer” complex, consisting of the METTL3/METTL14 enzy-
matic core and their regulator WT-associated protein (Frye
et al., 2018). The modification can be reversed by m6A de-
methylases (FTO and AlkBH5), collectively called “m6A eras-
ers.” m6A-modified transcripts are recognized by “m6A
readers,” including nuclear YTHDC1 (YTH domain-containing
1) and cytoplasmic YTH domain-containing family member
1 (YTHDF1), YTHDF2, YTHDF3, and YTHDC2, which execute
the outcome of m6A modification by promoting splicing,
nuclear export, translation, or degradation. Recent studies
demonstrated that loss of METTL3, METTL14, or FTO weakens
acute myeloid leukemia (AML) propagation, whereas inacti-
vation of METTL3 and METTL14 has deleterious consequences
for normal HSC maintenance (Barbieri et al., 2017; Cheng
et al., 2019; Li et al., 2017; Vu et al., 2017; Weng et al., 2018).
Furthermore, inactivation of YTHDF2, which recognizes
m6A-modified mRNA to mediate m6A-mRNA degradation (Du
et al., 2016; Wang et al., 2015), compromises initiation and
propagation of AML and results in HSC expansion (Li et al.,
2018; Paris et al., 2019; Wang et al., 2018). However, the in-
volvement of m6A or its readers in long-term HSC mainte-
nance upon aging remains unknown. Here, we reveal that
YTHDF2 functions to down-regulate m6A modified transcripts
involved in the inflammatory response and maintains HSC
integrity upon aging.
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Results and discussion
YTHDF2-deficient HSCs activate proinflammatory pathways
and lose their reconstitution capacity upon serial
transplantation
We have recently demonstrated that hematopoiesis-specific
Vav-iCre–mediated deletion of Ythdf2 results in HSC expansion
and compromises AML initiation and propagation (Paris et al.,
2019). We used the conditional and reporter Ythdf2fl mouse allele
in which exon 2 of Ythdf2was flanked by loxP sites and GFP was
introduced after the start codon of Ythdf2, generating a fully
functional GFP-YTHDF2 fusion protein (Ivanova et al., 2017).
Our published data indicated that 8–12-wk-old Ythdf2fl/fl;Vav-
iCre (conditional knockout, Ythdf2CKO) mice displayed largely
unaffected hematopoiesis compared with control Ythdf2fl/fl
(control, Ythdf2CTL) mice, with modest decreases in numbers of
white and red blood cells, B cells, and CD8+ T cells (Paris et al.,
2019). Furthermore, while HSCs from 8–12-wk-old Ythdf2CKO
mice displayed myeloid bias upon primary transplantation and
robustly contribute to the bone marrow (BM) HSC and pro-
genitor cell compartments (Paris et al., 2019), the role of
YTDHF2 in long-term HSC maintenance remains unknown. To
address this, we performed secondary transplantation assays
by sorting CD45.2+ Lin−c-Kit+Sca-1+ (LSK) cells from primary
recipients of Ythdf2CKO and Ythdf2CTL HSCs (Paris et al., 2019)
and retransplanting them (together with supporting BM cells)
into lethally irradiated secondary recipient mice (Fig. 1 A).
Strikingly, Ythdf2CKO HSCs failed to efficiently repopulate long-
term multilineage hematopoiesis and stem and progenitor cell
compartments in secondary recipients (Fig. 1, B–D) and dis-
played myeloid bias (Fig. S1 A). Thus, HSCs critically require
YTHDF2 to sustain their function upon serial transplantation.
To understand the cause of the failure of Ythdf2-deficient
HSCs upon serial transplantation, we next set out to deter-
mine the molecular signature of Ythdf2-deficient HSCs. Ythdf2
deficiency resulted in deregulated gene expression (Fig. 1 E),
with 81 up-regulated transcripts and 33 down-regulated tran-
scripts (false discovery rate [FDR] < 0.05) in Ythdf2CKO compared
with Ythdf2CTL HSCs. Strikingly, gene set enrichment analysis
(GSEA) on Ythdf2CKO versus Ythdf2CTL HSCs revealed significant
up-regulation of numerous inflammation-related processes,
such as IFN-α response, IFN-γ response, inflammatory response,
TNF-α signaling, and IL6/JAK/STAT3 signaling (Fig. 1 F and Fig.
S1 B).
Given that proinflammatory signals are known to drive
overproliferation of HSCs, ultimately resulting in loss of HSC
function (Essers et al., 2009; Pietras, 2017), we aimed to confirm
the proinflammatory signature in Ythdf2-deficient HSCs using
additional approaches. We found that HSCs from Ythdf2CKO mice
displayed increased expression of cell surface Sca-1 protein
(Fig. 1 G), which is used as a proxy of IFN signaling (Essers et al.,
2009). Furthermore, Ythdf2-deficient HSCs showed elevated
levels of phosphorylated forms of STAT1 and STAT3 proteins,
key mediators of IFN signaling (Fig. 1 H).
Given that Ythdf2-deficient HSCs showed up-regulation of
proinflammatory pathways and displayed a myeloid bias (a
hallmark of inflammation), we aimed to determine whether the
primitive progenitor compartment also reflected innate immune
activation in Ythdf2CKO mice. During steady-state normal he-
matopoiesis, HSCs generate functionally distinct lineage-biased
multipotent progenitors (MPPs), with MPP2/3 and MPP4
populations predominantly sustaining myeloid and lymphoid
lineages, respectively (Pietras et al., 2015). Stressful conditions
such as infection, stress, or injury induce proinflammatory
stimuli, which not only activate HSCs but also cause expansion of
MPPs, in particular myeloid-biased MPP2/3 populations, thereby
driving myeloid differentiation at the expense of HSC integrity
(Essers et al., 2009; Pietras et al., 2016; Yamashita and Passegue,
2019; Zhang et al., 2017; Zhang et al., 2016). Consistent with the
activation of proinflammatory pathways, we found that 8–12-wk-
old Ythdf2CKO mice displayed expansion of HSCs and a concurrent
increase in all four main subpopulations, namely MPP1-4 cells
(Fig. 1 I). Thus, hematopoietic-specific deletion of Ythdf2 results in
a constitutive up-regulation of the proinflammatory signature,
expansion of HSCs and MPPs, and a failure of HSC function upon
serial transplantation.
YTHDF2 functions to suppress m6A-modified proinflammatory
transcripts
YTHDF2 regulates the transcriptome by binding m6A modified
transcripts to promote their decay through deadenylation (Du
et al., 2016; Wang et al., 2014). To identify YTHDF2 target
transcripts, we aimed to determine mRNAs that were methyl-
ated in normal conditions and up-regulated in Ythdf2CKO HSCs.
m6A sequencing (m6A-seq) in c-Kit+ hematopoietic stem and
progenitor cells was used to determine transcriptome-wide m6A
distribution. This identified the expected distribution of m6A
within the transcriptome (i.e., enrichment around the stop co-
dons; Fig. 2, A and B) as well as the m6A consensus motif
(DRACH; D = A, G, or U; R = purine; and H = A, C, or U; Fig. 2 C).
Consistent with the role of YTHDF2 in promoting degradation of
m6A-modified transcripts, we found that transcripts that con-
tain m6A modification (P = 2.6 × 10−40, 8,253 genes) show in-
creased expression in Ythdf2CKO HSCs (Fig. 2 D). Ingenuity
pathway analysis (IPA) indicated that up-regulated genes are
enriched for transcripts related to inflammatory responses (in-
cluding IFN-γ, TNF-α, IFN-α, IFN regulatory factor 7, STAT1, and
TLR4; Fig. 2 E and Fig. S2 A). Importantly, m6A-seq revealed that
a large proportion of these key up-regulated transcripts in HSCs
are m6Amodified, including key genes involved in inflammation
such as Stat1, Il6ra, and Gadd45g (Fig. 2, E and F).
The up-regulation of m6A-modified transcripts involved in
inflammation upon loss of YTHDF2 may be a consequence of an
increase in their half-life. Given that the measurement of tran-
script half-life in HSCs is technically not possible, to address
this, we analyzed our SLAM-seq dataset from immortalized
c-Kit+ cells derived from Ythdf2CTL and Ythdf2CKO mice (Paris
et al., 2019), which allowed us to measure the transcriptome-
wide mRNA half-life (Herzog et al., 2017). We found that mul-
tiple m6A-modified transcripts that are up-regulated upon
Ythdf2 deletion (Fig. 2 E) also have their half-lives increased in
the absence of Ythdf2 (Fig. S2 B).
Finally, we next asked whether up-regulation of m6A-modi-
fied transcripts upon Ythdf2 deletion corresponds to an increase
in their protein level. Mass spectrometry can be used to obtain
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Figure 1. HSCs lacking Ythdf2 are expanded, activate proinflammatory pathways and prematurely lose function upon serial transplantation.
(A) Experimental design. 200 BM LSK CD48−CD150+CD45.2+ HSCs from 8-wk-old Ythdf2CKO and Ythdf2CTL mice were transplanted to lethally irradiated
syngeneic CD45.1+/CD45.2+ primary recipient mice together with 2 × 105 competitor CD45.1+ BM cells (Paris et al., 2019). After 16 wk, 2,000 CD45.2+LSK cells
were sorted from primary recipient mice and transplanted into lethally irradiated syngeneic CD45.1+/CD45.2+ secondary recipient mice together with 2 × 105
competitor CD45.1+ BM cells. PB of secondary recipient mice was analyzed every 4 wk, and hematopoietic compartments were analyzed 16 wk after
transplantation. (B) Percentage of CD45.2+ cells in the PB CD11b+Gr-1− monocyte, CD11b+Gr-1+ granulocyte, CD19+ B cell, and CD4+ and CD8+ T cell com-
partments of secondary recipient mice over 16 wk. Data represent mean ± SEM; *, P < 0.05; ****, P < 0.0001 (Mann–Whitney U test); at least two independent
experiments were performed. (C) Percentage of CD45.2+ cells in the BM and spleen overall and in the monocyte, granulocyte, B cell, and T cell compartments
of secondary recipient mice 16 wk after transplantation. Data represent mean ± SEM; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 (Mann–Whitney
U test); at least two independent experiments were performed. (D) Percentage of CD45.2+ cells in the BM of secondary recipients and in the LSK, LSK
CD48−CD150+ HSC, LSK CD48−CD150− MPP, LSK CD48+CD150− HPC-1, and LSK CD48+CD150+ HPC-2 cell compartments of secondary recipient mice 16 wk
after transplantation. Data represent mean ± SEM; *, P < 0.05; **, P < 0.01; ***, P < 0.001 (Mann–Whitney U test); at least two independent experiments were
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the comprehensive but incomplete quantitative measurement of
the proteome. IPA of quantitative mass spectrometry–based
proteomics of immortalized Ythdf2CTL and Ythdf2CKO c-Kit+ cells
indicated that up-regulated proteins are related to the same
inflammatory responses found in the transcriptomic data (Fig.
S2 A). Strikingly, based on the coverage of the proteomics da-
taset, we found that protein level of STAT1, IFN-γ inducible
protein 47, IFN-γ–induced GTPaseP, sterile α motif domain
containing 9 like, immunity-related GTPase family M protein 1,
and TNF receptor 2, whose corresponding transcripts were up-
regulated and methylated upon Ythdf2 deletion, were elevated in
Ythdf2-deficient cells (Fig. 2, G andH). Thus, YTHDF2 suppresses
m6A-modified mRNAs, which are involved in multiple proin-
flammatory pathways within HSCs. Given that Ythdf2 deletion
results in up-regulation of multiple m6A-modified transcripts in
HSCs, future genetic rescue experiments will reveal their rela-
tive contributions to their failure upon serial transplantation.
Aged HSCs lacking Ythdf2 undergo expansion and sustain
steady-state hematopoiesis but fail to reconstitute
multilineage hematopoiesis upon transplantation
Proinflammatory signals are known to drive overproliferation of
HSCs, promote myeloid bias, and ultimately lead to the loss of
HSC activity (Essers et al., 2009; Pietras, 2017). Furthermore,
proinflammatory pathways are up-regulated in aged HSCs, in-
dicating their roles in stem cell aging (Yamashita and Passegue,
2019). We found that both young and aged HSCs expressed
comparable levels of the YTHDF2 protein (Fig. S3 A). To inves-
tigate the functional significance of YTHDF2 in unperturbed
long-term multilineage hematopoiesis and maintenance of the
HSC pool over a long period of time, we aged Ythdf2CKO and
Ythdf2CTL mice for 1 yr (Fig. 3 A). Analyses of 60–65-wk-old
Ythdf2CKO mice revealed increased numbers of peripheral blood
(PB) granulocytes and monocytes (i.e., myeloid bias); however,
hematopoiesis was otherwise largely unaffected (Fig. 3, B and C;
and Fig. S3, B and C). Furthermore, 60–65-wk-old Ythdf2CKO
mice displayed expansion of BM HSCs and primitive hemato-
poietic progenitor cell populations (Fig. 3 D). HSCs from these
mice showed increased expression of Sca-1 (Fig. 3 E), indicating
constitutive activation of proinflammatory signals. To test
the ability of the expanded aged HSCs to reconstitute multi-
lineage hematopoiesis, we competitively transplanted HSCs
from 60–65-wk-old Ythdf2CKO and Ythdf2CTL mice into lethally
irradiated recipients (Fig. 3 A). While HSCs from aged Ythdf2CTL
mice robustly repopulated both myeloid and lymphoid lineages,
HSCs from aged Ythdf2CKO mice failed to efficiently reconsti-
tute short- and long-term multilineage hematopoiesis in the
recipients and displayed a myeloid bias (Fig. 3 F and Fig. S1 C).
The contribution of Ythdf2-deficient HSCs to the HSC com-
partment of the recipients was also decreased compared with
that of control HSCs (Fig. 3 G), albeit this was not as striking as
their inability to reconstitute multilineage hematopoiesis
(Fig. 1 F). Thus, while long-term Ythdf2 deficiency in the he-
matopoietic system does not derail steady-state multilineage
hematopoiesis, it devastates the multilineage reconstitution ca-
pacity of HSCs. Given that the inflammatory pathways affect
multiple HSC fates (Essers et al., 2009; Pietras, 2017; Pietras
et al., 2014; Pietras et al., 2016), future investigations will be
required to determine the exact impact of Ythdf2 deletion on HSC
survival, self-renewal, differentiation capacity, and homing.
Inducible Ythdf2 deletion results in a progressive loss of
lymphoid potential, with concurrent myeloid bias and
subsequent HSC failure
To delete Ythdf2 in adult mice in an inducible manner, we gen-
erated Ythdf2iCKO mice in which Ythdf2 can be ablated acutely
in hematopoietic cells upon administration of polyinosinic-
polycytidylic acid (pIpC). Ythdf2iCKO and Ythdf2CTL mice were
treated with pIpC and analyzed 26 and 52 wk later (Fig. 3 H).
Inducible Ythdf2 deletion resulted in increased myeloid output
(Fig. S3, D–F) and HSC expansion (Fig. S3 G), but multilineage
hematopoiesis was otherwise largely unaffected (Fig. S3, D–F).
Transplanted HSCs from mice 26 wk after Ythdf2 deletion re-
constituted myeloid lineages, failed to efficiently reconstitute
lymphoid lineages (Fig. 3 I and Fig. S1 D), and contributed
equally to the HSC compartment of recipients compared with
control HSCs (Fig. 3 J). Strikingly, HSCs from mice 52 wk after
Ythdf2 ablation failed to efficiently reconstitute both myeloid
and lymphoid lineages and displayed a myeloid bias (Fig. 3 K
and Fig. S1 E), while their ability to contribute to the HSC
compartment of the recipients was largely unaffected (Fig. 3 L).
Thus, inducible Ythdf2 deletion in adult mice causes a pro-
gressive loss of lymphoid output, myeloid bias upon aging, and
an eventual failure of aged HSCs to reconstitute long-term
multilineage hematopoiesis.
YTHDF2 protein expression in HSCs is induced by acute and
chronic inflammation
Given that YTHDF2 expression is induced by stress in other
contexts (Yu et al., 2019; Zhou et al., 2015) and is known to be
up-regulated in immune cells during the IFN response (Rubio
et al., 2018; Winkler et al., 2019), we hypothesized that YTHDF2
may itself be regulated by inflammatory stimuli in HSCs. To
address this, we used Ythdf2CTL mice harboring the GFP-YTHDF2
performed. (E) Transcript expression scatterplot from Ythdf2CKO and Ythdf2CTL HSCs from 8–12-wk-old mice (n = 4). Significantly dysregulated transcripts are
highlighted and counted (FDR < 0.05; log2 fold change < 1.2). (F) GSEA showing up-regulated pathways in HSCs from 8–12-wk-old Ythdf2CKO mice compared
with HSCs from Ythdf2CTL mice. (G) Histogram and median Sca-1 fluorescence intensity in LSK CD48−CD150+ HSCs from Ythdf2CKO and Ythdf2CTL mice de-
termined by flow cytometry. Data represent mean ± SEM; **, P < 0.01 (Mann–Whitney U test); at least two independent experiments were performed.
(H) Phospho-STAT1 and phospho-STAT3 levels in LSK cells determined by flow cytometry. Data represent mean ± SEM; *, P < 0.05 (Mann–Whitney U test); at
least two independent experiments were performed. (I) Total numbers of LSK cells, HSCs (LSK CD34−CD135−CD150+CD48−), and MPP1 (also referred to as
short-term HSCs; LSK CD34+CD135−CD150+CD48−), MPP2 (LSK CD34+CD135−CD150+CD48+), MPP3 (LSK CD34+CD135−CD150−CD48+), and MPP4 (LSK
CD34+CD135+CD150−CD48+) cell populations in BM of 8–12-wk-old Ythdf2CKO and Ythdf2CTL mice. Data represent mean ± SEM; ***, P < 0.001 (Mann–Whitney
U test); at least two independent experiments were performed. AU, arbitrary units; MFI, mean fluorescence intensity.
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fusion protein, inwhich GFP analyzed by flow cytometry reports
the expression of YTHDF2 protein. These mice were treated
with two or eight doses of pIpC to induce the IFN-α response and
model acute or chronic inflammation, respectively (Fig. 4 A).We
found a significant increase in the expression of GFP-YTHDF2
protein in HSCs under both conditions (Fig. 4, B–E). Given these
findings indicating that YTHDF2 is induced by inflammatory
stimuli, we next examined how loss of YTHDF2 impacts the
behavior of HSCs upon inflammation, by subjecting Ythdf2CTL
and Ythdf2CKO mice to pIpC-induced chronic inflammation
Figure 2. Ythdf2-deficient HSCs display up-regulation of m6A-modified transcripts involved in multiple proinflammatory pathways. (A)m6A-seq read
depth along a transcript body model for two replicate c-Kit+ Ythdf2CTL cell samples. Transcripts models were extended 400 nucleotides upstream and
downstream of the start and stop codons, respectively. (B) Location distribution of m6A peaks in gene regions. m6A peak overlaps with different transcript
regions (59 UTR; start codon; coding sequence, CDS; stop codon; 39 UTR). (C) Enriched m6Amotif found by Homer in peaks detected by macs2 v2.1.1.20160309.
(D) Violin plot of expression change between Ythdf2CTL and Ythdf2CKO BM LSK CD48−CD150+ HSCs (n = 4) from 8–12-wk-old mice for nonmethylated (nonm6A)
and methylated (m6A) transcripts determined by m6A-seq in c-Kit+ cells. (E) Heatmaps of genes representing IPA-defined IFN-γ, TNF-α, IFN-α, IFN regulatory
factor 7, STAT1 and TLR4 signaling pathways in Ythdf2CKO compared with Ythdf2CTL HSCs from 8–12-wk-old mice (n = 4). Transcript methylation peak presence
in two replicates from c-Kit+ cells depicted to the right by filled (m6A-modified) or unfilled (no m6A modification detected) circles. (F) m6A signal in key
transcripts involved in inflammatory responses. Read depth from two replicates of m6A immunoprecipitation (blue) and RNA-seq input (green). Transcript
regions are depicted as exonic (yellow) and intronic (gray). (G and H)Methylated proinflammatory transcripts up-regulated in Ythdf2CKO HSCs, which also show
increased protein abundance in immortalized Ythdf2CKO c-Kit+ cells (Paris et al., 2019). (G) Heatmap to left represents transcript abundance in HSC samples.
Transcript m6A modification in c-Kit+ cells is indicated in the center. Heatmap to right represents protein abundance in c-Kit+ cells. Heatmap colors represent
expression z-scores for a given row. (H) Peptide spectral counts (expressed as arbitrary units) from immortalized Ythdf2CTL and Ythdf2CKO c-Kit+ cells. Data
represent mean ± SEM; n = 5 per genotype; *, P < 0.05; **, P < 0.01 (Mann–Whitney U test). AU, arbitrary units.
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Figure 3. HSCs lacking Ythdf2 display a progressive myeloid bias and loss of stem cell activity upon aging. (A) Ythdf2fl/fl;Vav-iCre (Ythdf2CKO) and control
Ythdf2fl/fl (Ythdf2CTL) mice were aged for 1 yr, followed by analyses of their steady-state hematopoiesis (B–E). Furthermore, 200 BM LSK CD48−CD150+CD45.2+
HSCs were sorted and transplanted into lethally irradiated 8–10-wk-old syngeneic CD45.1+/CD45.2+ recipient mice (n = 12 per genotype) together with 2 × 105
CD45.1+ competitor BM cells (F and G). (B) PB counts of 60–65-wk-old Ythdf2CKO and Ythdf2CTL mice (n ≥ 5); P < 0.05 is highlighted in red. Data represent mean ±
SEM; at least two independent experiments were performed. (C) Total number of CD19+B220+ B cells, CD4+ T cells, CD8+ T cells, CD11b+Gr-1+ granulocytes,
and CD11b+Gr-1− monocytes in spleens of 60–65-wk old Ythdf2CKO and Ythdf2CTL mice (n ≥ 5). Data represent mean ± SEM; *, P < 0.05 (Mann–Whitney U
test); at least two independent experiments were performed. (D) Total number of HSCs, LSK CD48−CD150− MPPs, and primitive hematopoietic progenitor
cells (i.e., LSK CD48+CD150− HPC-1 and LSK CD48+CD150+ HPC-2 populations) in BM of 60–65-wk-old Ythdf2CKO and Ythdf2CTL mice (n ≥ 5). Data represent
mean ± SEM; **, P < 0.01 (Mann–Whitney U test); at least two independent experiments were performed. (E) Median Sca-1 fluorescence intensity in HSCs
from 60–65-wk-old Ythdf2CKO or Ythdf2CTL mouse BM determined by flow cytometry (n ≥ 5). Data represent mean ± SEM; *, P < 0.05 (Mann–Whitney U test);
at least two independent experiments were performed. (F) Percentage of CD45.2+ cells in the monocyte, granulocyte, B cell, and T cell compartments of
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before allowing recovery (Fig. 4 F). As in mice under steady-
state conditions (Paris et al., 2019; Fig. 1 I), primitive progenitor
cell populations (MPP2–4) were expanded in pIpC-treated
Ythdf2CKO mice compared with their Ythdf2CTL counterparts
(Fig. 4 G). Strikingly, however, unlike during steady-state
conditions in which Ythdf2-deficient HSCs andMPP-1 cells (also
referred to as short-term HSCs) were expanded (Paris et al.,
2019; Fig. 1 I), pIpC-treated Ythdf2CKO and Ythdf2CTL mice dis-
played comparable numbers of HSCs and MPP-1 cells
(Fig. 4 G). Therefore, while Ythdf2-deficient HSCs (which
recipients transplanted with HSCs from 60–65-wk-old CD45.2+ Ythdf2CKO or Ythdf2CTL mice (n = 12). Data represent mean ± SEM; ***, P < 0.001; ****, P <
0.0001 (Mann–Whitney U test); at least two independent experiments were performed. (G) Percentage of CD45.2+ cells in the BM HSC, MPP, HPC-1, and
HPC-2 cell compartments of recipient mice 16 wk after transplantation (n = 12). Data represent mean ± SEM; *, P < 0.05; **, P < 0.01 (Mann–Whitney U test);
at least two independent experiments were performed. (H) 8-wk-old Ythdf2fl/fl;Mx1-Cre (Ythdf2iCKO) and control Ythdf2fl/fl (Ythdf2CTL) mice were treated with
six sequential doses of plpC (given every alternate day) to induce deletion of Ythdf2. PB samples were taken at day 0 and over a 52-wk period after pIpC
treatment (Fig. S3 D). 200 BM LSK CD48−CD150+ CD45.2+ HSCs sorted from 34-wk-old (Fig. 3, I and J) and 60-wk-old (Fig. 3, K and L) Ythdf2CTL and
Ythdf2iCKO mice were transplanted into lethally irradiated syngeneic CD45.1+/CD45.2+ recipient mice together with 2 × 105 competitor CD45.1+ BM cells (n =
12). (I) Percentage of CD45.2+ cells overall in the monocyte, granulocyte, B cell, and T cell compartments of lethally irradiated recipient mice transplanted
with HSCs from 34-wk-old CD45.2+ Ythdf2iCKO or Ythdf2CTL mice (n = 12). Data represent mean ± SEM; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001
(Mann–Whitney U test); at least two independent experiments were performed. (J) Percentage of CD45.2+ cells in the BM HSC, MPP, HPC-1, and HPC-2 cell
compartments of recipient mice 16 wk after transplantation with HSCs from 34-wk-old Ythdf2iCKO or Ythdf2CTL mice (n = 12). Data represent mean ± SEM, at
least two independent experiments were performed. (K) Percentage of CD45.2+ cells overall in the monocyte, granulocyte, B cell, and T cell compartments
of lethally irradiated recipient mice transplanted with HSCs from 60-wk-old CD45.2+ Ythdf2iCKO or Ythdf2CTL mice (n = 12). Data represent mean ± SEM; *, P <
0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 (Mann–Whitney U test); at least two independent experiments were performed. (L) Percentage of
CD45.2+ cells in the BM HSC, MPP, HPC-1, and HPC-2 cell compartments of recipient mice 16 wk after transplantation with HSCs from 60-wk-old Ythdf2iCKO
or Ythdf2CTL mice (n = 12). Data represent mean ± SEM; at least two independent experiments were performed.
Figure 4. YTHDF2 expression responds to
acute and chronic inflammation. (A) Ythdf2fl/fl
(Ythdf2CTL) mice were treated with two doses of
plpC on days 0 and 2 before analysis on day 3
(Fig. 4, B and C) or treated with two doses of
plpC per week for 4 wk and allowed to recover
for 10 d before analysis (Fig. 4, D and E). Un-
treated littermate controls were analyzed at
equal time points. (B) Representative histogram
of modal YTHDF2-GFP fluorescence assayed by
flow cytometry in LSK CD48−CD150+ HSCs from
untreated littermate controls or mice treated
with two doses of plpC. At least two indepen-
dent experiments were performed. (C) Median
YTHDF2-GFP fluorescence intensity (MFI) of the
data presented in B (n = 3 and n = 8 biological
replicates, for treated and untreated, respec-
tively). Data represent mean ± SEM; *, P < 0.05;
(Mann–Whitney U test); at least two indepen-
dent experiments were performed. (D) Repre-
sentative histogram of modal YTHDF2-GFP
fluorescence assayed by flow cytometry in HSCs
from untreated littermate controls or mice trea-
ted with two doses of plpC weekly for 4 wk
followed by 10-d recovery before analysis. At
least two independent experiments were per-
formed. (E) YTHDF2-GFP MFI of the data shown
in D (n = 5 and n = 3 biological replicates, for
treated and untreated, respectively). Data rep-
resent mean ± SEM; *, P < 0.05 (Mann–Whitney
U test); at least two independent experiments
were performed. (F) Ythdf2fl/fl;Vav-iCre
(Ythdf2CKO) and control Ythdf2fl/fl (Ythdf2CTL) mice were treated with two doses of plpC per week for 4 wk and allowed to recover for 10 d before analy-
sis (Fig. 4 G). Furthermore, 200 LSK CD48−CD150+ CD45.2+ BM HSCs were sorted and transplanted into lethally irradiated 8–10-wk-old syngeneic CD45.1+/
CD45.2+ recipient mice (n = 12 per genotype) together with 2 × 105 CD45.1+ competitor BM cells (Fig. 4 H). (G) Total number of lineage−Sca-1+c-Kit+ LSK
cells, HSCs (LSK CD34−CD135−CD150+CD48−), MPP1 (LSK CD34+CD135−CD150+CD48−), MPP2 (LSK CD34+CD135−CD150+CD48+), MPP3 (LSK
CD34+CD135−CD150−CD48+), and MPP4 (LSK CD34+CD135+CD150−CD48+) cell populations in the BM of plpC-treated Ythdf2CKO or Ythdf2CTL mice. Data rep-
resent mean ± SEM; **, P < 0.01; ns, not significant (Mann–Whitney U test); at least two independent experiments were performed. (H) Percentage of CD45.2+
cells in the CD11b+Gr-1− monocyte, CD11b+Gr-1+ granulocyte, CD19+ B cell, and CD4+ or CD8+ T cell, compartments of recipients transplanted with HSCs from
plpC treatedYthdf2CKO or Ythdf2CTL mice 1 mo after transplantation (n = 12 and n = 13 recipients, respectively). Data represent mean ± SEM; ***, P < 0.001; ****,
P < 0.0001 (Mann–Whitney U test); at least two independent experiments were performed.
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display up-regulated proinflammatory pathways) undergo ex-
pansion under steady-state conditions, additional inflamma-
tory stimuli abrogate this phenotype.
Finally, to investigate whether Ythdf2 deficiency in HSCs had
any impact on their short-term reconstitution potential upon
pIpC administration, we competitively transplanted equal
numbers of HSCs from pIpC-treated Ythdf2CKO and Ythdf2CTL
mice into lethally irradiated recipients (Fig. 4 F). HSCs lacking
Ythdf2 displayed decreased short-termmyeloid and B-lymphoid
reconstitution capacity, indicating that inflammation tempo-
rarily weakened Ythdf2-deficient HSC activity (Fig. 4 H). Thus,
our data indicate that YTHDF2 is induced by inflammation in
HSCs and suggest that YTHDF2 may function to protect HSCs
from excessive proinflammatory signals. The mechanisms through
which YTHDF2 is induced by inflammation, and its precise in-
volvement in protecting HSCs in this context, remain important
open questions meriting further investigations.
Collectively, YTHDF2 expression is induced in HSCs by in-
flammatory stimuli and its deletion results in constitutive acti-
vation of proinflammatory pathways, consistent with myeloid
bias. While YTHDF2 is not essential for long-term steady-state
unperturbed hematopoiesis upon aging, Ythdf2 deletion causes
progressive HSC expansion and failure of HSCs to reconstitute
multilineage hematopoiesis. Because the activation of inflam-
matory pathways in HSCs by infections or injury causes their
proliferation and myeloid cell production, but in the longer term
compromises HSC activity (Esplin et al., 2011; Essers et al., 2009;
Pietras, 2017; Takizawa et al., 2017), HSCs must use mechanisms
to counteract these signals and protect their long-term integrity.
While several studies indicated that proinflammatory signals are
suppressed in HSCs at different levels of gene expression, in-
cluding cell signaling, gene transcription, and RNA editing
(Hartner et al., 2009; King et al., 2011; Sato et al., 2009), the
functional significance of dynamic RNA modifications in this
important aspect of HSC biology remains poorly understood. We
suggest that them6A-dependent mRNA decay pathway is a novel
mechanism through which HSCs suppress inflammation and
sustain HSC integrity. Interrogation of up-regulated proin-
flammatory genes upon Ythdf2 deficiency in genetic rescue ap-
proaches is warranted to further support this notion. Given our
findings that YTHDF2 itself is induced by inflammation, we
suggest that YTHDF2 may function in a negative feedback loop
to prevent an excessive inflammatory response detrimental to HSC
function. Thus, our work sets the stage for further investigations
focusing on howYTHDF2 regulates HSC fates during inflammation
upon acute and chronic infection. In closing, our data position
YTHDF2 as an essential repressor of proinflammatory pathways in
HSCs and highlight the key significance of m6A mRNA modifica-
tion in long-term HSC maintenance upon aging.
Materials and methods
Mice
All mice were on the C57BL/6 background (backcrossed for ≥10
generations). Ythdf2fl/fl, Vav-iCre, and Mx1-Cre strains have been
described previously (de Boer et al., 2003; Ivanova et al., 2017;
Kühn et al., 1995). Congenic recipient mice were CD45.1+/CD45.2+.
All experiments involving mice were performed under Uni-
versity of Edinburgh Veterinary oversight with UK Home Of-
fice authorization. All control mice were littermates, and
treatment groups were randomized among littermates.
Flow cytometry
BM and splenic cells were prepared and analyzed as described
previously (Guitart et al., 2017; Guitart et al., 2013; Kranc et al.,
2009; Mortensen et al., 2011; Paris et al., 2019; Vukovic et al.,
2016). Hematopoietic stem and progenitor cell staining began
with incubation with Fc block followed by biotin-conjugated
anti-Lineage marker antibodies (anti-CD4, anti-CD5, anti-CD8a, anti-
CD11b, anti-B220, anti-Gr-1, and anti-Ter119), APC-conjugated anti-c-
Kit, APC-Cy7–conjugated anti-Sca-1, PE-conjugated anti-CD48, andPE-
Cy7–conjugated anti-CD150 antibodies. Biotin-conjugated lineage
markers were then stained with PerCP-conjugated streptavi-
din. Staining of MPP1–4 populations was performed as above
for hematopoietic stem and progenitor cells; however, BV711-
instead of APC-conjugated anti-c-Kit was used and cells were
also stained with APC-conjugated anti-Flt3– and BV421-conjugated
anti-CD34 antibodies.
For PB and differentiated cell analysis, cells were stained
with PerCP-conjugated anti-B220, APC-Cy7–conjugated anti-
CD19, Pacific Blue–conjugated anti-CD11b, PE-Cy7–conjugated
anti-Gr-1, APC-conjugated anti-CD8, and PE-conjugated anti-
CD4 antibodies. To distinguish CD45.2 chimerism in transplan-
tation experiments, BV711-conjugated anti-CD45.1 and Pacific
Blue–conjugated anti-CD45.2 antibodies were used. For hemato-
poietic stem and progenitor cell staining in transplanted mice,
APC-conjugated anti-c-Kit and APC-Cy7-conjugated anti-Sca-1 were
used; the remainder of the staining was as described above. For
analyses of differentiated cells and PB in transplanted mice, cell
suspensions were stained with BV711-conjugated anti-CD45.1,
Pacific Blue–conjugated anti-CD45.2, APC-conjugated anti-CD11b,
PE-Cy7–conjugated anti-Gr-1, PE-conjugated anti-CD4 and -CD8a,
and APC-Cy7–conjugated anti-CD19. Flow cytometry analyses
were performed using a LSRFortessa (BD Biosciences). Cell sort-
ing was performed on a FACSAria Fusion (BD Biosciences).
Intracellular staining and flow cytometry analysis
BM and splenic cells were prepared and analyzed as described
previously (Guitart et al., 2017; Guitart et al., 2013; Kranc et al.,
2009; Mortensen et al., 2011; Paris et al., 2019; Vukovic et al.,
2016) followed by c-Kit enrichment (described below). Cells
were incubated with Fc block and stained with biotin-conjugated
anti-Lineage marker antibodies (anti-CD4, anti-CD5, anti-CD8a, anti-
CD11b, anti-B220, anti-Gr-1, and anti-Ter119), APC-Cy7–conjugated
anti-c-Kit, and Pacific Blue–conjugated anti-Sca-1. Biotin-conjugated
Lineage markers were then stained with PerCP-conjugated Streptavi-
din. Cells were then fixed and permeabilized using Phosflow Lyse/Fix,
Phosflow Perm Buffer III, and stain buffer (all from BD Biosciences)
according to the manufacturer’s instructions. After processing, cells
were stained with AF647-conjugated anti-pStat1 or anti-pStat3.
Syngeneic transplantation assays
Transplant recipient CD45.1+/CD45.2+ mice were lethally irra-
diated with two doses of 5.5 Gy administered ≥4 h apart at an
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average rate of 0.58 Gy/min using a cesium-137 GammaCell 40
irradiator. For primary transplantations, irradiated recipient
CD45.1+/CD45.2+ mice were intravenously injected with 200
LSK CD48−CD150+ HSCs and 200,000 support CD45.1+ un-
fractionated BM cells. For secondary transplantations, recipient
CD45.1+/CD45.2+ mice were intravenously injected with 2,000
CD45.2+ LSK cells or 100,000 c-Kit–enriched BM cells from
primary recipients and 200,000 support CD45.1+ unfractionated
BM cells. All recipient mice were culled and analyzed 16–20 wk
after transplantation. A minimum of two independent donor
mice were used for all transplantations.
pIpC administration
For gene deletion via activation of the Mx1-Cre promotor, mice
were injected i.p. every other day with 300 µg pIpC (GE
Healthcare) for a total of six doses over 11 d, as previously de-
scribed (Guitart et al., 2017; Guitart et al., 2013; Kranc et al.,
2009; Paris et al., 2019), and gene deletion was assayed by
YTHDF2-GFP fusion protein fluorescence. To test the effect of
innate immune activation, mice were injected i.p. with 300 µg
pIpC (GE Healthcare) as described per experiment.
CD117 (c-Kit) enrichment
Enrichment for cells expressing CD117 (c-Kit) was performed
using CD117 MicroBeads and LS columns from Miltenyi Biotec,
according to the manufacturer’s instructions.
Histology
Tibias and femurs were dissected and cleaned before fixation in
4% paraformaldehyde for 24 h. Fixed bones were decalcified,
embedded in paraffin, and sectioned. Sections were stained with
H&E and mounted. Whole sections were imaged using a Vectra
Polaris slide scanner, and representative images were taken at
10× and 20× magnification.
RNA-seq
100 HSCs per sample were sorted into 0.4% Triton X-100, RNase
inhibitor, 10 mM dNTPs, and 10 µM Oligo dT before RNA-seq by
SMART-Seq2 in the Single Cell Genomics Facility at the Medical
Research Council Weatherall Institute of Molecular Medicine
(University of Oxford). Alignments to the GRCm38 mouse ge-
nome were performed using HISAT2 (Kim et al., 2015), and
further analysis was performed in R. Counts were assigned to
genes using the Rsubread package, and quality control analysis
of the samples was performed with the SingleCellExperiment
and scater packages. Differentially expressed genes were iden-
tified using likelihood ratio tests computed by the edgeR pack-
age. The RNA-seq dataset was deposited in GEO (accession no.
GSE142019).
m6A meRIP-seq
m6A meRIP-seq library preparation was performed as previ-
ously described (Lin et al., 2016) from Ythdf2CTL c-Kit–enriched
cells. Reads from two biological replicates were aligned to the
mouse GRCm38 genome using HISAT2 (Kim et al., 2015), and
peaks were called using MACS2, version 2.1.1 with the nom-
odel flag (Zhang et al., 2008). To analyze the distribution of
m6A-associated reads along the transcripts, treat_pileup bed-
graph file outputs from MACS2 were converted to bigWig
format and used as input for the computeMatrix function of the
deepTools package, version 2.5.5 (Ramı́rez et al., 2014). Motif
enrichment was done using Homer, version 4.10, selecting a
motif length of six nucleotides. Background regions were
generated by shuffling peaks along the transcriptome using the
shuffleBed tool from the bedtools suite, version 2.28 (Quinlan
and Hall, 2010). The GVIZ bioconductor package was used for
peak visualization (Hahne and Ivanek, 2016). m6A meRIP-seq
dataset was deposited in GEO (accession no. GSE142020).
GSEA and IPA
GSEA was performed using GSEA software version 3.0 with
1,000 permutations and default parameters. Gene differential
expression, computed by the edgeR package in R, was ranked by
moderated t statistics, which takes into account variability be-
tween genes in the ranking. Ranked genes were compared with
gene lists in the Hallmark subset of the MSigDB database, ver-
sion 7.0. IPA was performed using the Core Analysis Function
offered by Qiagen’s Ingenuity Pathway Analysis software
(Krämer et al., 2014). The interrogated RNA-seq and mass
spectrometry datasets were filtered for adjusted P values of
differential expression (FDR < 0.05), and the threshold for
significant activation or inhibition was defined by an absolute
Z-score value >2.
SLAM-seq analysis
The SLAM-seq dataset (Paris et al., 2019) was analyzed using the
SlamDunk pipeline (Herzog et al., 2017).
Mass spectroscopy analysis
Immortalized Ythdf2CKO and Ythdf2CTL c-Kit–enriched cells (Paris
et al., 2019) were pelleted, lysed, and processed according to
(Wiśniewski and Rakus, 2014). Tryptic peptides were analyzed
on a QExactive+ mass spectrometer connected to an Ultimate
Ultra3000 chromatography system packed with 1.8 µm uChrom
and separated by an acetonitrile gradient. Mass spectra were
analyzed using MaxQuant against the Uniprot mouse database
proteome, ID UP000000589.
Quantification and statistical analysis
Statistical analyses were performed using Prism 6 software
(GraphPad Software). P values were calculated using a two-
tailed Mann–Whitney U test unless stated otherwise.
Online supplemental material
Fig. S1 shows the frequency of B cells, T cells, granulocytes, and
monocytes within the CD45.2+ donor-derived population of PB,
BM, and spleen from transplant recipients shown in Figs. 1 B;
and 3 F, I, and K. Also shown are GSEA plots from RNA-seq of
Ythdf2CKO and Ythdf2CTL HSCs from Fig. 1 F. Fig. S2 shows IPA of
RNA-seq and mass spectrometry from Ythdf2CKO and Ythdf2CTL
cells and mRNA decay curves for transcripts of interest within
Ythdf2CKO and Ythdf2CTL c-Kit+ cells. Fig. S3 shows data to sup-
port our conclusions in aged mice (YTHDF2-GFP mean fluo-
rescence is not significantly altered with age; aged mice have
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normal BM cellularity and histology); percentage of monocytes,
granulocytes, CD4+ T cells, CD8+ T cells, B cells, and GFP+ cells
in PB from mice 1 yr after Ythdf2 deletion; and total blood
counts, numbers of differentiated cells, and numbers of HSCs
for mice 1 yr after Ythdf2 deletion.
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Figure S1. Molecular and cellular features of Ythdf2-deficient HSCs. (A) BM LSK CD48−CD150+CD45.2+ HSCs from 8-wk-old Ythdf2CKO and Ythdf2CTL mice
were transplanted to lethally irradiated syngeneic CD45.1+/CD45.2+ primary recipient mice together with 2 × 105 competitor CD45.1+ BM cells (as published in
Paris et al., 2019). After 16 wk, 2,000 CD45.2+ LSK cells were sorted from primary recipient mice and transplanted into lethally irradiated syngeneic CD45.1+/
CD45.2+ secondary recipient mice together with 2 × 105 competitor CD45.1+ BM cells (as described in Fig. 1 A). The frequency of CD19+ B cells, CD4+ or CD8+
T cells, CD11b+Gr-1+ granulocytes, and CD11b+Gr-1− monocytes in the CD45.2+ compartment of PB, BM, and spleen of secondary transplanted mice was
analyzed 16 wk after transplantation. Analysis of the percentage of CD45.2+ cells in each compartment is presented in Fig. 1, B and C (n = 12). Data represent
mean ± SEM; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 (Mann–Whitney U test); at least two independent experiments were performed.
(B) HSCs lacking Ythdf2 display proinflammatory gene signatures. GSEA of differential gene expression in Ythdf2CKO versus Ythdf2CTL HSCs from young animals.
Results for five significant (FDR < 0.1) inflammation-related categories are shown (Hallmark, MSigDB v6.2). Genes were ordered by log P value but ranked in the
same sense as log fold-change. (C) Ythdf2CKO and control Ythdf2CTL mice were aged for 1 yr before sorting and transplantation of 200 BM LSK
CD48−CD150+CD45.2+ HSCs into lethally irradiated 8–10-wk-old syngeneic CD45.1+/CD45.2+ recipient mice (n = 12) together with 2 × 105 CD45.1+ competitor
BM cells (as described in Fig. 3 A). After 16 wk, the frequency of B cells, T cells, granulocytes, and monocytes in the CD45.2+ compartment of PB, BM, and spleen
of recipient mice was analyzed. Analysis of the percentage of CD45.2+ cells within lineages and stem cell compartments is presented in Fig. 3, F and G. Data
represent mean ± SEM; *, P < 0.05; ***, P < 0.001; ****, P < 0.0001 (Mann–Whitney U test); at least two independent experiments were performed. (D and E)
8-wk-old Ythdf2fl/fl;Mx1-Cre (Ythdf2iCKO) and control Ythdf2fl/fl (Ythdf2CTL) mice were treated with six sequential doses of plpC (every other day) to induce
deletion of Ythdf2. BM LSK CD48−CD150+ CD45.2+ HSCs were sorted from 34-wk-old (D) and 60-wk-old (E) Ythdf2CTL and Ythdf2iCKO mice (as described in
Fig. 3 H) before transplantation into lethally irradiated syngeneic CD45.1+/CD45.2+ recipient mice together with 2 × 105 competitor CD45.1+ BM cells. The
frequency of B cells, T cells, granulocytes, and monocytes in the CD45.2+ compartment of PB, BM, and spleen of recipient mice was analyzed 16 wk after
transplantation. Analysis of the percentage of CD45.2+ cells in lineage and stem cell compartments is presented in Fig. 3, I–L (n = 12). Data represents mean ±
SEM; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 (Mann–Whitney U test); at least two independent experiments were performed.
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Figure S2. Molecular properties of HSCs lacking Ythdf2. (A) IPA of RNA-seq and mass spectroscopy from Ythdf2CTL and Ythdf2CKO HSCs or c-Kit+ cells,
respectively. Z-score represents the degree of activation of the pathway, with a threshold for significance set at 2. P value shown refers to the overlap between
target genes or proteins in the dataset and target genes in the IPA database. RNA-seq, n = 4; proteomics, n = 5. (B) Decay curves for transcripts in Ythdf2CTL
(upper panels) and Ythdf2CKO (lower panels) c-Kit+ cells are shown. The center value and the error bars at each time point indicate the conversion rate mean
and SD, respectively. Conversion rates for each biological replicate are indicated with dots. The half-life for each graph is also shown.
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Figure S3. Inducible deletion of Ythdf2 from adult mice does not derail long-term steady-state hematopoiesis but results in a progressive myeloid
bias and HSC failure upon aging. (A) Modal YTHDF2-GFP fluorescence assayed by flow cytometry in LSKs and LSK CD48−CD150+ HSCs from 8–12-wk-old
and 60–65-wk-old Ythdf2CTL mice. Data represent mean ± SEM; ns, not significant (Mann–Whitney U test); at least two independent experiments were
performed. (B) Total BM cellularity of one leg from 60–65-wk-old Ythdf2CTL and Ythdf2CKO mice (n ≥ 5). Data represent mean ± SEM; at least two independent
experiments were performed. (C) Representative sections of H&E-stained Ythdf2CTL and Ythdf2CKO BM at 10× and 20× magnification (n ≥ 5). (D) Percentage of
CD19+B220+ B cells, CD4+ T cells, CD8+ T cells, CD11b+Gr-1+ granulocytes, CD11b+Gr-1− monocytes, and GFP-YTHDF2+ cells in PB of Ythdf2iCKO and Ythdf2CTL
mice over 12 mo after pIpC treatment. Bottom right, loss of expression of GFP-YTHDF2 following pIpC treatment (n ≥ 5). Data represents mean ± SEM; *, P <
0.05; **, P < 0.01; ***, P < 0.001 (Mann–Whitney U test); at least two independent experiments were performed. (E) PB counts of Ythdf2CTL and Ythdf2iCKO
mice 12 mo after pIpC treatment (n = 5–8). Data represent mean ± SEM; P value by Mann–Whitney U test; at least two independent experiments were
performed. (F) Total number of differentiated cell populations in BM and spleens 12 mo after pIpC treatment (n = 5–9). Data represent mean ± SEM; *, P < 0.05;
***, P < 0.001 (Mann–Whitney U test); at least two independent experiments were performed. (G) Total cell numbers of BM primitive cell populations. HSCs,
LSK CD48−CD150+ HSCs; MPP, LSK CD48−CD150−; HPC-1, LSK CD48+CD150−, HPC-2 LSK CD48+CD150+, and LK Lin−Sca-1−c-Kit+ myeloid progenitors 12 mo
after pIpC treatment (n = 5–9). Data represent mean ± SEM, *, P < 0.05 (Mann–Whitney U test); at least two independent experiments were performed.
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